Note: Ingredients listed on restricted chemical lists
EC/CAS
63-42-3
Name of the chemical
Lactose C12H22O11
Concentration
N/A
EC/CAS
14807-96-6
Name of the chemical
Talc
Concentration
N/A
EC/CAS
77-93-0
Name of the chemical
citric acid, triethyl ester
Concentration
N/A
General Information
Revision date
2012-11-16
Product name
915-OMEPRAZOLE DELAYED RELEASE TABLETS 20 mg
supplier name
Perrigo Company
Icons in SDS
Company Information
company name
Perrigo Company
e-mail address of the competent person responsible for the Safety Data Sheet
blackey@perrigo.com
Section 2
SECTION 2: Hazards identification
OSHA Emergency Overview May cause eye irritation May be harmful if swallowed in amounts above the therapeutic dose Consumers: Refer to the package insert for consumer-specific information about the directional use and effects of this product Only information about the ingredients that are expected to contribute to the potential health effects of the product are included in this MSDS Do not use if printed seal under cap is broken or missing Appearance White Physical State Solid. Odor No information available OSHA Regulatory Status Over-the counter drugs in their final form as sold to the consumer are considered exempt under the criteria of the Federal OSHA Communication Standard 29CFR1910.1200. However, if exposure may occur in the industrial setting, outside of personal use, the occupational exposure limits may be exceeded and may be considered hazardous.
Principle Routes of Exposure
Skin contact. Ingestion. Do not take more than directed. See dosing chart for more information. Acute Toxicity Eyes May cause irritation Skin No known effect based on information supplied. Inhalation No known effect based on information supplied Ingestion No known effect when taken as indicated. Ingestion at levels above recommended values may be harmful. See package insert for further information.
Potential chronic health
Titanium dioxide has been classified by the International Agency for Research on Cancer (IARC) as possibly carcinogenic to humans (Group 2B) by inhalation This product contains titanium dioxide in a non-respirable form. Inhalation of titanium dioxide is unlikely to occur from exposure to this product
Medical Conditions Generally Aggravated by Exposure
Gastrointestinal tract. If pregnant or breast feeding ask a health professional before use. 20 mg _____________________________________________________________________________________________
Interactions with other chemicals
Ask a doctor or pharmacist before use if you are taking: Warfarin, clopidogrel or cilostazol (blood-thinning medicines) Prescription anti-fungal or anti-yeast medicines. Diazepam (anxiety medicine) Digoxin (heart medicine) Tacrolimus (immune system medicine) Prescription antiretrovirals (medicine for HIV infection)
Environmental hazards
See Section 12 for additional Ecological information.